New updates have been reported about Insilico Medicine.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Insilico Medicine has secured FDA Investigational New Drug (IND) clearance for ISM8969, an orally available, brain-penetrant NLRP3 inhibitor for Parkinson’s disease, marking a key advancement in the company’s AI-driven clinical portfolio and U.S. development strategy. The Phase I trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers and determine the recommended dose for subsequent studies, positioning ISM8969 as a potential best-in-class asset in neuroinflammation. Discovered and optimized using Insilico’s Chemistry42 generative chemistry engine within its broader Pharma.AI platform, ISM8969 has demonstrated blood-brain barrier penetration, a favorable druggability profile, and efficacy in inflammatory and chronic disease mouse models, which collectively strengthen its commercial and partnering potential in central nervous system indications.
To accelerate global development and de-risk commercialization, Insilico has entered into a 50/50 co-development collaboration with Hygtia Therapeutics, granting Hygtia worldwide rights to research, develop, register, manufacture, and commercialize ISM8969, while Insilico remains entitled to up to $66 million in upfront and milestone payments. The deal adds to Insilico’s broader AI-enabled partnering track record, which already includes major pharma collaborations with an aggregate potential contract value of up to $2.1 billion, and underscores the monetization pathway for its AI-originated pipeline. Backed by its ability to compress early-stage discovery timelines to 12–18 months and limit synthesized molecules per program, Insilico is using ISM8969 as a flagship example of its model for rapidly advancing preclinical candidates into human studies, with implications for future dealmaking, portfolio value, and the company’s positioning as a listed AI biotech on the Hong Kong Stock Exchange (3696.HK).